Enlicitide vs HRS-1301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Enlicitide · Lipfendra
Marketed by Merck & Co.
NCT05952856 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.
Next expected readout: November 2027 · NCT07821944 (registry estimate)
Reported efficacy
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)
Result source: NCT05952856
HRS-1301
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT06857253 · Phase 1 · completed
This is a real randomized, blinded, placebo-controlled study, which is a solid design, but its primary measure is adverse-event safety monitoring rather than a cholesterol or cardiovascular outcome, and results have not been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enlicitide | HRS-1301 |
|---|---|---|
| LDL-C, % change | -58.2% vs 2.6%−60.8 vs placeboNCT059528696 other results
| —Not reported |
| Non-HDL-C, % change | -52.3% vs 2.1%−54.4 vs placeboNCT059528695 other results
| —Not reported |
| ApoB, % change | -48.2% vs 1.8%−50 vs placeboNCT059528695 other results
| —Not reported |
| Lp(a), % change | -24.7% vs -1.6%−23.1 vs placeboNCT059528691 other result
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT07216482 | —Not reported |
LDL-C, % change
- Enlicitide
- -58.2% vs 2.6%−60.8 vs placeboNCT05952869
6 other results
- -64.6% vs -36.5% NCT06450366
- -55.3% vs 8.7% NCT05952869
- -59.7% vs 1.2% NCT05261126
- -57.9% vs 1.2% NCT05261126
- -54.5% vs 1.2% NCT05261126
- -40% vs 1.2% NCT05261126
- HRS-1301
- —Not reported
Non-HDL-C, % change
- Enlicitide
- -52.3% vs 2.1%−54.4 vs placeboNCT05952869
5 other results
- -58% vs -31.8% NCT06450366
- -54.3% vs 1.5% NCT05261126
- -51.8% vs 1.5% NCT05261126
- -49% vs 1.5% NCT05261126
- -34.4% vs 1.5% NCT05261126
- HRS-1301
- —Not reported
ApoB, % change
- Enlicitide
- -48.2% vs 1.8%−50 vs placeboNCT05952869
5 other results
- -54.6% vs -27.7% NCT06450366
- -51.8% vs 0% NCT05261126
- -48.7% vs 0% NCT05261126
- -45.8% vs 0% NCT05261126
- -32.8% vs 0% NCT05261126
- HRS-1301
- —Not reported
Lp(a), % change
- Enlicitide
- -24.7% vs -1.6%−23.1 vs placeboNCT05952869
1 other result
- -26.2% vs 10.4% NCT06450366
- HRS-1301
- —Not reported
3-point MACE (% with event)
- Enlicitide
- —Not posted · NCT07216482
- HRS-1301
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-1301: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Enlicitide: 3 of 4 rows · HRS-1301: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Enlicitide |
|---|---|
| Dropout rate | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results3% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 1%Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results— NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —30 mg NCT05261126 · Phase 2 · registry result, not featured evidence —18 mg NCT05261126 · Phase 2 · registry result, not featured evidence —12 mg NCT05261126 · Phase 2 · registry result, not featured evidence —6 mg NCT05261126 · Phase 2 · registry result, not featured evidence —Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence —Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence —Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence —Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 9.9%20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results4.5% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 3.9%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 1.3%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 9.4% (placebo 7.9%) influenza 8.4% (placebo 8.9%) accidental overdose 7.9% (placebo 4%) NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 9 more results30 mg covid-19 5.3% (placebo 9.3%) arthralgia 2.6% (placebo 1.3%) nausea 2.6% (placebo 0%) NCT05261126 · Phase 2 · registry result, not featured evidence 18 mg covid-19 6.6% (placebo 9.3%) nausea 5.3% (placebo 0%) diarrhoea 3.9% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence 12 mg dyspepsia 6.6% (placebo 1.3%) arthralgia 5.3% (placebo 1.3%) fatigue 3.9% (placebo 6.7%) NCT05261126 · Phase 2 · registry result, not featured evidence 6 mg covid-19 7.8% (placebo 9.3%) diarrhoea 6.5% (placebo 1.3%) dyspepsia 1.3% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence dry mouth 12.5% hypertension 12.5% animal bite 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 12.5% orthostatic hypotension 12.5% dry mouth 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Enlicitide
show 6 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · HRS-1301's landscape